The BMJ report describes the trajectory of an experimental surgical treatment for Alzheimer’s disease and the legal and regulatory consequences for its pioneer. Qingping Xie, a microsurgeon and president at Hangzhou Qiushi Hospital, performed the first deep cervical lymphatic-venous anastomosis (dcLVA) on a patient six years ago after obtaining ethical approval from his hospital. The procedure subsequently expanded rapidly across China, drew international media interest, and later prompted regulatory and legal action in China while trials progressed overseas.
Deep cervical lymphatic-venous anastomosis involves microsurgical connection of extremely thin lymphatic vessels to a vein in the neck. The technique is established in other contexts such as treatment for lymphoedema, but Xie adapted it with the hypothesis that improved lymphatic drainage from the neck could help clear brain toxic proteins implicated in Alzheimer’s disease. The BMJ article notes that the technique was refined by Joon Pio Hong, but provides no further technical or mechanistic details beyond the broad conceptual rationale.
dcLVA gained rapid popularity in China and received prominent coverage in major scientific outlets, including articles in Science (2025) and Nature (2026). The BMJ piece reports that the procedure’s expansion was swift, leading to many patients undergoing an invasive operation despite an absence of randomised trial evidence. The article highlights that enthusiasm and uptake outpaced the generation of robust efficacy data.
Criticism documented in the source centres on multiple fronts. Clinicians and commentators questioned the lack of randomised evidence demonstrating benefit, the absence of standardised surgical technique across practitioners, and the procedure’s high price for patients. The BMJ also reports concerns about potential surgical complications and the ethical implications of offering an experimental invasive intervention to a population that includes vulnerable people with cognitive impairment. These issues were central to the debate that preceded regulatory intervention.
Chinese authorities banned the dcLVA operation in July 2025, citing insufficient robust clinical evidence for efficacy. The BMJ report states that two months after the ban Qingping Xie was arrested on suspicion of insurance fraud; the article notes that no criminal charges had been publicly announced at the time of reporting. The source does not provide further specifics about the arrest, any investigations, or legal proceedings beyond these points.
Despite the Chinese ban and the limited evidence base, the BMJ notes that clinical trials of dcLVA are proceeding internationally, including in the United States and other countries. The article questions how an invasive, weakly evidenced operation achieved rapid dissemination and asks what the early international trials currently reveal. The BMJ piece, as provided, does not report specific trial designs, enrolment numbers, outcomes, or interim data. It therefore does not provide concrete results from those international trials.
The situation reported raises several practical and ethical considerations for clinicians, investigators, and research governance bodies. Key issues include the need for standardised surgical protocols when evaluating invasive procedures, the importance of randomised controlled trials to establish efficacy, transparent reporting of adverse events, and careful consent processes for patients with cognitive impairment. The BMJ article draws attention to the tension between clinical innovation and evidence-based practice but does not issue clinical recommendations.
The source article leaves several details unreported. It does not present randomised trial data demonstrating benefit or harm from dcLVA, nor does it provide specific information on the protocols, endpoints, recruitment, or preliminary outcomes of the international trials mentioned. Detailed information about the circumstances of Qingping Xie’s arrest, any formal criminal charges, and the legal basis for detention was not reported. The BMJ story therefore highlights public and scientific concerns while noting gaps in available evidence and official disclosures.